Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the efficacy and safety of QMF149 a combination of indacaterol acetate and mometasone furoate compared to budesonide in children aged 6 to less than 12 years who have asthma. This Phase 3, double-blind, randomized, active-controlled crossover study aims to determine whether QMF149 is superior in improving lung function measured by FEV1 in these children, who have at least 50% of the predicted normal value of FEV1. Participants undergo two treatment periods, each lasting 12 weeks, receiving either QMF149 7540 mcg once daily via Breezhaler or budesonide 200 mcg once daily via Breezhaler in a crossover design. The study includes a screening period of up to 3 weeks, a 3-week run-in period with fluticasone propionate 50 mcg twice daily, a 3-week washout period with the same medication, and a 4-week safety follow-up during which participants return to standard care. The total study duration is up to 37 weeks. Throughout the study, participants will attend visits at defined intervals, including screening, run-in, treatment, washout, and follow-up periods. Researchers will assess lung function changes FEV1, asthma control questionnaire scores, peak expiratory flow rates, rescue medication use, and monitor adverse events. Safety information and survival status will be collected after the follow-up period to ensure thorough evaluation of both treatments.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease COPD who are already receiving inhaled maintenance therapy and have experienced recent COPD exacerbations. This Phase 3, multicenter, randomized, double-blind, placebo-controlled study aims to understand how tezepelumab impacts COPD outcomes compared to a placebo. Participants will receive monthly subcutaneous injections of one of two doses of tezepelumab or a matching placebo. The treatment period lasts a minimum of 52 weeks and up to 76 weeks. Following treatment, there is a 12-week safety follow-up without active treatment to monitor participants. Throughout the study, participants will be monitored regularly to assess lung function, COPD symptoms, and exacerbation rates. Researchers will collect data on lung function tests, symptom questionnaires, and exacerbation frequency up to 76 weeks. Blood samples will be taken to study drug levels and immune responses. The total participation time for each individual includes the treatment period plus the safety follow-up phase.
Actively Recruiting
Researchers are evaluating the effects of an isoinertial training program on muscle strength and functional capacity in older adults diagnosed with moderate to severe chronic obstructive pulmonary disease COPD. COPD causes systemic changes, including muscle dysfunction that limits patients abilities and quality of life. Isoinertial training may improve muscle mass, neuromuscular efficiency, and functional performance in this population. The study is a randomized controlled clinical trial involving 30 participants aged 50 to 80 years. Participants will be randomly assigned to either a supervised isoinertial training program or a control group following the usual pulmonary rehabilitation program. The intervention lasts 8 weeks with 2 to 3 sessions per week, focusing on upper and lower limb strengthening using an isoinertial device with progressively increased load. The control group maintains traditional rehabilitation exercises without isoinertial training. Participants will undergo initial assessments including tests of muscle strength, functional capacity, clinical parameters, and sociodemographic data. Outcomes measured at baseline and after 8 weeks include upper and lower limb strength, functional mobility, muscle quality, and functional performance through various tests like the Hand Grip Test and 6-minute walk test. Secondary measures include quality of life, body mass index, heart rate, blood pressure, and oxygen saturation. Safety and adherence will be monitored throughout the study period.
Actively Recruiting
Researchers are evaluating the effects of inhaled glycopyrronium bromide in children aged 6 to less than 12 years with moderate to severe asthma. This Phase II study aims to compare two doses of glycopyrronium with a placebo to understand their bronchodilator effects, systemic exposure, safety, and tolerability. The results will help determine the appropriate dose for a fixed combination inhaler treatment for this pediatric population. The study is designed as a double-blind, placebo-controlled, randomized crossover trial with three treatments glycopyrronium bromide 12.5 g, glycopyrronium bromide 25 g, and placebo. Each participant receives all three treatments in different sequences over three two-week treatment periods separated by two-week washouts. Participants continue their background asthma controller therapy throughout. The total treatment phase lasts 10 weeks, preceded by screening and run-in phases, followed by a safety follow-up. Participants will undergo screening, followed by a run-in phase to confirm eligibility and assess inhaler technique. During treatment, lung function tests including forced expiratory volume in one second FEV1 are measured at the start and end of each treatment period. Pharmacokinetic samples, symptom assessments, rescue medication use, and adverse event monitoring occur regularly. Safety follow-up includes a telephone contact 30 days after the last treatment. The total study duration per participant is about 20 weeks.
Actively Recruiting
This trial focuses on participants with autoimmune and inflammatory conditions who have previously taken part in a Novartis study involving secukinumab. It aims to evaluate the long-term safety of secukinumab in those who continue to benefit from the treatment but cannot access the marketed version. The study is a Phase 4, open-label extension designed to provide ongoing assessment of this medication. Participants will receive secukinumab injections under the skin at doses of 75 mg, 150 mg, or 300 mg every four weeks, depending on their previous treatment dose in the parent trial. Pediatric dosing will be limited according to weight categories and prior evaluated maximum doses. Investigators can adjust doses based on clinical needs and health authority guidance. This study involves a single group receiving secukinumab with no placebo or comparator. During the study, participants will be monitored for up to two years to assess the occurrence of any adverse or serious adverse events. The trial will involve regular evaluations to track the participants safety while continuing secukinumab treatment. The total duration for participation can extend until the study ends in 2030, with ongoing safety assessments throughout this period.